NASDAQ:GLYC - GlycoMimetics Stock Price, Forecast & News

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

GlycoMimetics Inc (NASDAQ:GLYC) issued its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.08. View GlycoMimetics' Earnings History.

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for GlycoMimetics.

6 brokerages have issued 1 year price targets for GlycoMimetics' shares. Their forecasts range from $5.00 to $18.00. On average, they anticipate GlycoMimetics' share price to reach $9.25 in the next twelve months. This suggests a possible upside of 136.6% from the stock's current price. View Analyst Price Targets for GlycoMimetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.

News stories about GLYC stock have trended somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GlycoMimetics earned a news impact score of 1.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for GlycoMimetics.

Some companies that are related to GlycoMimetics include Eagle Pharmaceuticals (EGRX), Omeros (OMER), Phoenix Tree (IMAB), Cara Therapeutics (CARA), Flexion Therapeutics (FLXN), Molecular Templates (MTEM), Kadmon (KDMN), Emisphere Technologies (EMIS), RAPT Therapeutics (RAPT), Vectura Group (VEGPF), Akero Therapeutics (AKRO), Basilea Pharmaceutica (BPMUF), G1 Therapeutics (GTHX), Urogen Pharma (URGN) and BioXcel Therapeutics (BTAI).

Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), Agile Therapeutics (AGRX), Viking Therapeutics (VKTX), Amarin (AMRN), TG Therapeutics (TGTX), Vanda Pharmaceuticals (VNDA), Fate Therapeutics (FATE), Nabriva Therapeutics (NBRV), Pieris Pharmaceuticals (PIRS) and Amicus Therapeutics (FOLD).

GlycoMimetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include AXA (2.18%), State Street Corp (1.48%), Geode Capital Management LLC (1.13%), Oxford Asset Management LLP (0.31%), Panagora Asset Management Inc. (0.27%) and Bank of New York Mellon Corp (0.26%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.

GLYC stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Alambic Investment Management L.P., State Street Corp, Bank of New York Mellon Corp, Bank of America Corp DE and Geode Capital Management LLC. View Insider Buying and Selling for GlycoMimetics.

GLYC stock was acquired by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Panagora Asset Management Inc., Jacobs Levy Equity Management Inc., California Public Employees Retirement System, Virtus ETF Advisers LLC, UBS Group AG, AXA and AQR Capital Management LLC. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il and Daniel M Junius. View Insider Buying and Selling for GlycoMimetics.

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GLYC stock can currently be purchased for approximately $3.91.

GlycoMimetics has a market capitalization of $169.54 million. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.

The official website for GlycoMimetics is http://www.glycomimetics.com/.

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]